StockNews.AI
DXCM
StockNews.AI
3 hrs

DexCom, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights – DXCM

1. DexCom faces allegations of misleading shareholders regarding product reliability. 2. Class period for claims runs from July 2024 to September 2025. 3. Allegations include unauthorized design changes to G6 and G7 products. 4. Health risks associated with devices may lead to regulatory ramifications. 5. Deadline for lead plaintiff registration is December 26, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations against DexCom suggest severe product reliability issues, historically leading to significant stock declines during similar situations in the tech and health industries.

How important is it?

The serious nature of the allegations can create substantial legal and operational risks, impacting stock value.

Why Long Term?

Legal proceedings can take considerable time, affecting ongoing investor confidence and stock performance for months or years.

Related Companies

MDLZINTCABT
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=176107&from=3 CLASS PERIOD: July 26, 2024 to September 17, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes to The Company’s glucose monitoring products, the G6 and G7, unauthorized by the U.S. Food and Drug Administration; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. DEADLINE: December 26, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=176107&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of DXCM during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 26, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News